Zetagen Therapeutics, founded 2015, private clinical-stage biopharmaceutical company develops first-of-its-kind targeted ...

AstraZeneca is planting its flag in the oral SERD space, touting positive Phase 3 breast cancer data for a program it expects ...

Checkpoint therapies like Keytruda, Opdivo, and Imfinzi are expanding from late-stage to early-stage cancer treatment, with ...

The CDC will no longer recommend routine Covid-19 vaccines for healthy kids and pregnant women after HHS Secretary Robert F.

Novo Nordisk warned the US government not to impose pharma-specific tariffs, but instead to tax illegal importers of ...

Arvinas' vepdegestrant shows 43% reduced risk of progression or death in ESR1-mutated breast cancer patients vs hormone ...

AstraZeneca/Daiichi's Enhertu shows survival benefit vs standard care in HER2+ gastric cancer patients, with 14.7 vs 11.4 ...

Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: ...

Prothena abandons birtamimab after Phase 3 amyloidosis trial failure, plans layoffs. Drug previously failed mid-stage trial.

The Column Group's drug R&D team, known as TCG Labs Soleil, has been busy churning out new portfolio companies since it ...

After a slight delay, the FDA rejected Stealth BioTherapeutics' Barth syndrome drug application for elamipretide, but will ...

Summit Therapeutics' ivonescimab shows 48% PFS benefit but misses OS endpoint in Phase 3 lung cancer trial; drug's regulatory ...